Compare
Amphastar Pharmaceuticals, Inc. vs Pacira BioSciences, Inc. vs Emergent BioSolutions Inc. vs Corcept Therapeutics Inc
| Latest fiscal year | Amphastar Pharmaceuticals, Inc. AMPH | Pacira BioSciences, Inc. PCRX | Emergent BioSolutions Inc. EBS | Corcept Therapeutics Inc CORT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $719.89M | $726.41M | $742.90M | $761.41M |
| Revenue growth (YoY) | -1.7% | +3.6% | -28.8% | +12.8% |
| Gross margin | 49.5% | 79.4% (computed) | 56.1% (computed) | n/a |
| Operating margin | 19.5% | 2.6% | 13.5% | 5.9% |
| Net margin | 13.6% | 1.0% | 7.1% | 13.1% |
| Net income | $98.09M | $7.03M | $52.60M | $99.65M |
| EPS (Diluted) | $2.03 | $0.16 | $0.93 | $0.82 |
| Operating cash flow | $156.12M | $151.99M | $170.60M | $142.00M |
| Free cash flow | $121.23M | $136.66M | $156.80M | $141.78M |
| Cash & equivalents | $170.18M | $158.54M | $205.40M | $120.50M |
| Total assets | $1.63B | $1.26B | $1.32B | $836.65M |
| Total liabilities | $840.49M | $571.81M | $796.00M | $188.85M |
| Shareholders' equity | $788.80M | $693.11M | $522.60M | $647.80M |
| Return on year-end equity | 12.4% | 1.0% | 10.1% | 15.4% |
| Shares outstanding | 45.65M | 41.12M | 52.10M | 105.97M |
Revenue, most recent five fiscal years
| Fiscal year | Amphastar Pharmaceuticals, Inc. | Pacira BioSciences, Inc. | Emergent BioSolutions Inc. | Corcept Therapeutics Inc |
|---|---|---|---|---|
| Latest | $719.89M Ended 2025-12-31 | $726.41M Ended 2025-12-31 | $742.90M Ended 2025-12-31 | $761.41M Ended 2025-12-31 |
| 1 year earlier | $731.97M Ended 2024-12-31 | $700.97M Ended 2024-12-31 | $1.04B Ended 2024-12-31 | $675.04M Ended 2024-12-31 |
| 2 years earlier | $644.39M Ended 2023-12-31 | $674.98M Ended 2023-12-31 | $1.05B Ended 2023-12-31 | $482.38M Ended 2023-12-31 |
| 3 years earlier | $498.99M Ended 2022-12-31 | $666.82M Ended 2022-12-31 | $1.12B Ended 2022-12-31 | $401.86M Ended 2022-12-31 |
| 4 years earlier | $437.77M Ended 2021-12-31 | $541.53M Ended 2021-12-31 | $1.77B Ended 2021-12-31 | $365.98M Ended 2021-12-31 |